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A recently published randomized controlled trial in JAMA investigated the impact of the
selective serotonin reuptake inhibitor, escitalopram, on the risk of major adverse events
(MACE). The authors estimated a hazard ratio (HR) of 0.69 (95% CI: 0.49, 0.96; p = 0.03)
and thenattempted to calculatehowmuchstatistical power their study (test) hadattained,
and used thismeasure to assess how reliable their results were. Here, we discusswhy this
approach, along with other post-hoc power analyses, are highly misleading.
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1 | BACKGROUND
Kim et al. [1] present the data from a randomized trial
showing that treatment with escitalopram for 24 weeks low-
ered the risk of major adverse cardiac events (MACE) in de-
pressed patients following recent acute coronary syndrome.
The authors should be commended for exploring new ap-
proaches to reduce major cardiac events. However, in their
paper, they seem to misunderstand the purpose of statisti-
cal power. In statistical hypothesis testing, power is the pre-
study probability of correctly rejecting the test hypothesis,
such as a null hypothesis, given a correct alternative hypothe-
sis [2]. This is a frequentist probability, so it is calculated with
multiple replications of the same design in mind. Power anal-
yses can be useful for designing studies but lose their utility
after the study data have been obtained and analyzed [3].
In the design phase, Kim et al. [1] used data from the Ko-
rea Acute Myocardial Infarction Registry (KAMIR) study [4]
and estimated the power of their design to be 70% and 96%
for detecting 10% and 15% group differences, respectively,
with a sample size of 300 participants. This is often referred
toas “designpower.” It is basedon the studydesign andbeliefs
about the true population structure. After completing the
study and analyzing the data, the authors attempted to calcu-
late how much power their test had based on the estimated
hazard ratio (HR = 0.69, 95%CI: 0.49, 0.96; p = 0.03). They es-
timated that their test had 89.7% power to detect between-
group differences in MACE incidence rates. This is often re-
ferred to as “observed power” because it is calculated from
the estimated effect size from the study data [3]. This form of
power analysis is extremely misleading.
One cannot know the true power of a statistical test be-
cause there is no way to be sure that the effect size estimate
fromthe study (HR=0.69) is thepopulationeffect size. There-
fore, one cannot be certain that the observed power (89.7%) is
the true power of the test. Observed power can often mislead
researchers into having a false sense of confidence in their re-
sults. Furthermore, observed power, which is a 1:1 function
of the P-value, yields no relevant information not already pro-
vided by the P-value [3, 5]. This also remains true for studies
that are pooled in meta-analysis and then analyzed for aver-
age statistical power, which has recently gained momentum.
However, this yields unstable interval estimates in even the
most ideal of conditions [6].
Statistical power can be useful for designing studies, but
once thedata froma studyhavebeenproduced, it is theeffect
sizes, theP-values, and the confidence/compatibility intervals
that contain insightful information. Observed power adds lit-
tle to this and can be misleading [3, 5, 6]. If one wishes to see
how cautious they should be about their point estimate, then
they should lookat thewidthof the interval estimates and the
parameter values they cover [2, 7].
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